“At Qu, we don’t do things just because that’s the way they are always done. We stop to ask why? Opportunity lies in the ‘why?'”

~ Dr. Hal Gunn, CEO

Qu 3 scientists_wide2

Be part of the paradigm shift

Qu Biologics is a private clinical-stage biotechnology company developing Site Specific Immunomodulators (SSIs). SSIs are at the forefront of a paradigm shift in the treatment of cancer and other immune-related diseases. Research literature is increasingly recognizing the important underlying role of innate immune system dysfunction, specifically macrophage dysfunction, in the development of cancer, inflammatory bowel disease and a host of other chronic inflammatory diseases.

Since 2007, Qu has focused on the opportunity inherent in the SSI platform, which is designed to provide a simple and safe means to restore innate immune function in the targeted organ or tissue by recruiting activated macrophages to the disease organ. Read about How SSIs Work and Efficacy and Safety.

Qu Biologics has completed three Phase 2 clinical trials, demonstrating proof-of-concept in Crohn’s disease, ulcerative colitis, and recurrent lung cancer. Plans are now underway for a multi-centre clinical trial in Crohn’s disease, to be initiated in two stages, starting in 2018.

With a prestigious leadership team, an innovative platform of immunotherapies, and promising clinical and preclinical data, Qu Biologics is poised to lead the paradigm shift in how cancer and other immune-related diseases will be treated. We invite discussions with potential partners.

If you would like to work with an innovative, driven clinical-stage biopharmaceutical company dedicated to putting promising new immunotherapies into the hands of patients, Qu Biologics is currently seeking partners to move forward their QBECO program in IBD and to expand their current clinical trial program to include additional indications in cancer and/or immune-related disease.

If you are interested in learning more about Qu and our partnering opportunities, please enter your contact information here.